AstraZeneca Submits sNDA for SYMBICORT® for COPD Treatment
- Details
- Category: AstraZeneca
AstraZeneca today announced submission of a supplemental New Drug Application (sNDA) to the US Food and Drug Administration (FDA) to seek approval of a new indication for SYMBICORT® (budesonide/formoterol fumarate dihydrate) Inhalation Aerosol for the treatment of patients with Chronic Obstructive Pulmonary Disease (COPD).
Novo Nordisk will donate a licence to its small molecule compound library
- Details
- Category: Novo Nordisk
Novo Nordisk will donate a licence to its small molecule compound library to the National Center for Drug Screening (NCDS) affiliated to Shanghai Institute of Materia Medica, Chinese Academy of Sciences. The centre will use the library â both the actual compounds and an associated database â for screening activities to identify new drug candidates for infectious tropical diseases that affect people in poor countries.
Follicular lymphoma: EU approval for Zevalin® as First-Line Consolidation Treatment
- Details
- Category: Bayer
The European Commission has extended the marketing authorization for Zevalin® ([90Y]-ibritumomab tiuxetan) in Europe. Zevalin can now be used in the course of a first-line therapy after remission induction in previously untreated patients with follicular lymphoma. The aim of such a consolidation therapy is the improvement of the effect of an initial induction therapy.
Amgen's First Quarter 2008 Adjusted Earnings Per Share Increased 4 percent to $1.12
- Details
- Category: Amgen
Amgen (NASDAQ:AMGN) reported adjusted earnings per share (EPS), excluding stock option expense and certain other expenses, of $1.12 for the first quarter of 2008, an increase of 4 percent compared to $1.08 for the first quarter of 2007. Adjusted net income, excluding stock option expense and certain other expenses, decreased 4 percent to $1,218 million in the first quarter of 2008 compared to $1,270 million in the first quarter of 2007.
Pfizer Enters into Research Consortium to Expand Understanding of Diabetes and Obesity Pathobiology
- Details
- Category: Pfizer
Pfizer has entered into a collaboration agreement with four major research universities â University of California, Santa Barbara (UCSB); Caltech; the Massachusetts Institute of Technology; and University of Massachusetts â and Entelos, a physiological modeling company, to re-examine the regulatory mechanisms of human energy metabolism.
Two Merck Medicines Recommended for Approval in the European Union
- Details
- Category: Merck
Merck & Co., Inc. announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency has recommended two medicines for marketing approval in the European Union (EU).
GlaxoSmithKline will acquire Sirtris Pharmaceuticals for approximately USD720 million
- Details
- Category: GlaxoSmithKline
GlaxoSmithKline (NYSE: GSK) and Sirtris Pharmaceuticals Incorporated (Nasdaq: SIRT) announced that they have entered into a definitive agreement pursuant to which GlaxoSmithKline will acquire Sirtris Pharmaceuticals for approximately USD720 million (or approx. GBP362 million) through a cash tender offer of USD22.50 (or approx. GBP11.33) per share.
More Pharma News ...
- AstraZeneca PLC First Quarter Results 2008
- Genzyme Reports Strong First-Quarter Growth
- Novartis reports higher sales and earnings in first quarter of 2008
- Novartis announces 20% average reduction in price of malaria drug Coartem®
- The Medicines Company Reports First Quarter 2008 Financial Results
- Environmentally Responsible Site to Significantly Increase Company's Presence in China
- Results from phase 2b "DEEP" study in severe pre-eclampsia